It is inspired by a Viewpoint discussing the challenge of using the 20% blast threshold in bone marrow to distinguish myelodysplastic syndromes (MDS) from acute myeloid leukaemia (AML). The article suggests that this boundary may be too simplistic and points to other features that can help tell these diseases apart, including genetic markers that reveal specific mutations.